Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02911922 |
Recruitment Status
:
Recruiting
First Posted
: September 22, 2016
Last Update Posted
: August 22, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Device: Endorectal Balloon Device: Rectal Spacer Radiation: Radiation therapy | Not Applicable |
This is a randomized, two arm study for patients with low-risk or favorable intermediate-risk prostate cancer as defined by 1.2016 NCCN criteria.
Patients will be randomized to either rectal spacer placement or endorectal balloon placement, daily prior to each radiation treatment.
- Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.
- Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.
This study plans to enroll a total of 40 patients with an accrual period of 4 years.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer |
Study Start Date : | September 2016 |
Estimated Primary Completion Date : | September 2019 |
Estimated Study Completion Date : | September 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Endorectal balloon - Radiation therapy
Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days. |
Device: Endorectal Balloon
Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
|
Experimental: Rectal spacer - Radiation therapy
Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days. |
Device: Rectal Spacer
Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days. Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
|
- To assess acute GI/GU toxicity [ Time Frame: 4 years ]To compare acute GI/GU toxicity (as defined by CTCAE v4.0) and to compare Rectal dose (V35, max rectal dose)
- Health-related quality of Life questionnaire [ Time Frame: 5 years ]To compare health-related quality of life (HRQOL) measured using the Expanded Prostate Cancer Index Composite (EPIC) instrument for bowel, urinary and sexual domains
- To measure recurrence-free survival [ Time Frame: 5 years ]To compare biochemical recurrence-free survival at 1, 2 and 5 years
- To compare radiation dose distribution of the two techniques [ Time Frame: 5 years ]
To compare the dose distribution of the 2 techniques, specifically:
- coverage of the PTV
- DVH of organs at risk (OAR)
- prostate motion and shifts required during treatment
- To assess late GI/GU toxicity [ Time Frame: 5 years ]To compare late GI/GU toxicity (as defined by CTCAE v4.0)
- To explore changes in the microbiome that is associated with normal tissue toxicities resulting from radiation [ Time Frame: 5 years ]To explore microbiome changes associated with normal tissue toxicities resulting from radiation
- To compare blood count (CBC) measurements at different time points to assess impact of SBRT [ Time Frame: 5 years ]To collect complete blood count (CBC) measurements at pre-treatment, 1, 3 , 6 and 12 months post-treatment to assess impact of SBRT, if any, on baseline values

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 99 Years (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy-proven diagnosis of prostate adenocarcinoma, diagnosed within 1 year of randomization
- Either NCCN-defined low-risk disease (T1c-T2a, Gleason score 3+3=6, PSA <10), intermediate-risk disease (Gleason score 3+4=7, 4+3=7, T2b-c and/or PSA 10-20; ) or high-risk disease due to Gleason score 8-10 and/or PSA >20 ng/ml, but not due to T3-T4 disease on physical exam.
Exclusion Criteria:
- History of prior pelvic radiation (external beam or brachytherapy)
- Prior or concurrent lymphomatous/hematogenous malignancy, or history of prior/concurrent invasive malignancy during the past 5 years
- Very high risk prostate cancer (T3b-T4 on clinical exam, Primary Gleason pattern 5, or >4 cores with Gleason score 8-10)
- History of prior chemotherapy for prostate cancer
- History of irritable bowel disease
- Evidence of lymph node involvement
- AUA score >15
- Prostate size > 90 cc

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02911922
Contact: Sharanya Chandrasekhar, M.S. | 212-746-7277 | shc2043@med.cornell.edu | |
Contact: Christina Castro, B.S | 212-746-2546 | chc2071@med.cornell.edu |
United States, New York | |
Weill Cornell Medicine | Recruiting |
New York, New York, United States, 10065 | |
Contact: Sharanya Chandrasekhar, M.S. 212-746-7277 shc2043@med.cornell.edu | |
Contact: Christina Castro, B.S. 212-746-2546 chc2071@med.cornell.edu | |
Principal Investigator: Josephine Kang, M.D. |
Principal Investigator: | Josephine Kang, M.D. | Weill Cornell Medicine - New York Presbyterian Hospital | |
Principal Investigator: | Silvia Formenti, M.D. | Weill Cornell Medicine - New York Presbyterian Hospital |
Responsible Party: | Weill Medical College of Cornell University |
ClinicalTrials.gov Identifier: | NCT02911922 History of Changes |
Other Study ID Numbers: |
1604017139 |
First Posted: | September 22, 2016 Key Record Dates |
Last Update Posted: | August 22, 2017 |
Last Verified: | August 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Additional relevant MeSH terms:
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |